ARECOR LISTED IN BUSINESS WEEKLY’S ‘KILLER50’

Hot on the heels of our first clinical trials approval, Arecor is delighted to be listed in Business Weekly’s ‘Killer50’, as a leading lifescience innovator. Please see the listing and feature here on Page 12: Link

ARECOR RECEIVES REGULATORY APPROVAL TO INITIATE PHASE I CLINICAL TRIAL FOR ULTRA-RAPID ACTING INSULIN PRODUCT

Cambridge, UK., 20 March 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im […]

ARECOR APPOINTS CHIEF FINANCIAL OFFICER

Cambridge (UK), 11th March 2019, Arecor Limited (‘Arecor’ or the ’Company’), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect […]

Super-fast-acting Prandial Insulin Product Receives £0.5m Innovate UK Boost

Super-fast product addresses critical unmet need in development of next generation artificial pancreas systems” “Novel formulation significantly accelerates absorption of insulin post injection – accelerating the onset of glucose lowering.” Cambridge, UK., 13 February 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for […]

Arecor to attend the 37th Annual J.P. Morgan Healthcare Conference

ARECOR LIMITED (“Arecor” or “the Company”) ARECOR TO ATTEND THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Cambridge, UK., 5 December 2018: Arecor Ltd (“the Company”), the UK-based specialty pharmaceutical company that develops superior biopharmaceuticals through the application of an innovative formulation technology platform, is pleased to announce today that its executive management team, Dr Sarah […]

Arecor successfully defends a key European patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage

Cambridge, UK., 30th October 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, continues to build a strong patent portfolio protecting the Company’s proprietary technology and product assets. Arecor is pleased to announce the successful outcome of the opposition proceedings […]

Arecor Joins Elite Investor Roadshow to China

ARECOR LIMITED (“Arecor” or “the Company”) ARECOR JOINS ELITE INVESTOR ROADSHOW TO CHINA “Arecor has joined the London Stock Exchange Group’s latest ELITE mission to China for aspiring companies and will participate in investor roadshow events, in Shenzhen and Hong Kong, between 15th – 18th October 2018” Cambridge, UK., 15 October 2018: Arecor Limited (“the […]

Biopharma Company Arecor raises £6m for revolutionary diabetes treatments

10 September 2018 – Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures.  BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures. Through the […]